Clinical trial · Observational
Effect of Pre-Transplant Tyrosine Kinase Inhibitors in Hepatocellular Carcinoma Patients With Liver Transplantation
Efficacy and Safety of Pre-Transplant Tyrosine Kinase Inhibitors in Hepatocellular Carcinoma Patients Undergoing Liver Transplantation
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Based on the follow-up data of hepatocellular carcinoma (HCC) patients undergoing liver transplantation from the China Liver Transplant Registry (CLTR) and the First Affiliated Hospital of Xi'an Jiaotong University, patients who met the inclusion criteria were assessed for tumor response, post-transplant tumor recurrence, and survival rates. Statistical analysis was performed to evaluate patient prognosis and to identify risk factors affecting outcomes.
Conditions
Conditions (4)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hepatocellular Carcinoma (HCC) | Hepatocellular Carcinoma | ONTOLOGY_EXACT | 0.85 |
| Liver Transplantation | — | UNRESOLVED | — |
| Survival Rate | — | UNRESOLVED | — |
| Tyrosine Kinase Inhibitor | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Medication history | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- TKIs group
- description
- The TKIs group was defined as patients who received at least 28 days of tyrosine kinase inhibitor therapy (including sorafenib, lenvatinib, regorafenib, or donafenib) prior to liver transplantation. According to the inclusion and exclusion criteria, subjects meeting this group's characteristics were screened from the database, and the group's data were collected and recorded for subsequent analysis.
- interventionNames
- Other: Medication history
- label
- No TKIs group
- description
- The No TKIs group was defined as patients who did not receive tyrosine kinase inhibitor therapy (including sorafenib, lenvatinib, regorafenib, or donafenib) prior to liver transplantation. According to the inclusion and exclusion criteria, subjects meeting this group's characteristics were screened from the database, and the group's data were collected and recorded for subsequent analysis.
- interventionNames
- Other: Medication history
Primary outcomes (3)
- measure
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: 1. Age ≥ 18 years and ≤ 75 years; 2. HCC diagnosis confirmed through imaging and elevated serum alpha-fetoprotein (AFP); 3. Underwent liver transplantation for hepatocellular carcinoma. 4. Underwent primary (first-time) liver transplantation. 5. Availability of complete clinical and follow-up data for analysis. Exclusion Criteria: 1. age \<18 years or \>75 years; 2. living-donor liver transplantation or re-transplantation; 3. concurrent active malignancy other than HCC; 4. incomplete key baseline data or follow-up information.
References
Publications (1)
- DERIVEDXu L, Zhao Z, Wang Z, Zhao Z, Mu F, Zhou C, Ye Z, Zhang X, Wang Y, Lan T, Cao W, Zhang Y, Qi J, Hou Y, Shi J, Lu J, Tian M, Lv Y, Qu P, Hu L, Wang B. Association of Pre-Transplant Tyrosine Kinase Inhibitor Therapy With Tumor Response and Survival in Hepatocellular Carcinoma: A 10-Year Retrospective Cohort Study of 427 Patients. World J Surg. 2026 Jul 9. doi: 10.1002/wjs.70454. Online ahead of print. PMID 42421575